Canntab Therapeutics was founded on April 20, 2016 by pharmaceutical industry professionals who saw an urgent need to add industry rigour and professionalism to the medicinal cannabis market. We are the first company solely dedicated to the research and development of oral dosage therapeutic formulations of cannabis. We started by developing unique, patent pending technology which has resulted in the creation of a range of oral dosage products that effectively treat different ailments by delivering a uniform dosage of medicinal cannabis extract. Each is available in different dosage levels, available in instant and stable extended release.
Simply put, Canntab is a game changer in the medicinal cannabis market.
Unlike most cannabis brands, Canntab Therapeutics comes at the medicinal cannabis market from a pharmaceutical perspective, providing the medical community and patients with several advantages:
Through our dedication to research, we have identified the most medically effective cannabis strains and combined them with other active ingredients to create a range of tablets to better treat different ailments.
Making these mixtures available in tablet, capsule and flash melt form allows us to offer different dosage levels with uniform amount of ingredient in each tablet. No guessing required.
Our patented XR (extended release) technology means that our tablets deliver active ingredients in a stable, consistent manner over time, providing the same amount of effective relief for hours.
Our research has proven that oral dosage is a more effective delivery mechanism for cannabanoids and other ingredients to enter the blood stream, than is smoking or ingesting edibles. This increased bio-availability allows Canntab XR Tablets to deliver patient treatment very favourably.
Our oral dosage products provide effective medical relief without the negative side effects of other delivery options, such as smoking marijuana or eating gummy bears.
Our dedication to the research and development of innovative new cannabis based therapies doesn’t stop at extended release tablets. We are currently in advanced development of other new formulations and products that continue our mission of putting the “medical” into medicinal cannabis.
We have developed unique bi-layered tablets that offer an immediate dosage and therefore immediate release of active ingredients, combined with our patent-pending extended release formulations. This is a step forward for patients offering the best of both worlds – both immediate and extended relief. As with our XR tablets, each bi-layered tablet contains a uniform dosage, available in different levels, making it easier for doctors and patients alike to find and manage dosage levels that work best for individual patients.
Canntab Therapeutics Gel Capsules offer doctors and patients a uniform amount of THC/CBD oil extract, in a quick dissolving gel capsule offering immediate relief from symptoms. As with all of our products, our gel capsules are available in varying dosage levels, with each capsule containing the exact same amount of active ingredient for easy management.
Our flash melts are designed to dissolve immediately when placed under the tongue. They deliver an immediate dosage to the patient, offering instant relief. Our flash melt products are offered in different formulations depending on the medical need and have a uniform dosage offering the medical advantages of all our other products.
These and other products in development and available for international licensing, are part of our on-going dedication to bring new, innovative, pharmaceutical industry standard products to the medicinal cannabis market.
With a rapidly growing medicinal cannabis market in both Canada and the US, and Canada moving towards full legalization in 2018, the market is estimated to grow 20 times in the next five years. Canntab Therapeutics, with our range of oral dosage products based on our patent-pending technology, is poised to become a leader in the industry.
Founded by people with deep experience in therapeutic drug development, investment management and regulatory law, we are truly putting the “medical” into the medicinal cannabis market. Our extended release tablets are simply a step forward in medicinal cannabis, finally offering the medical community and patients a reliable, professional, medical solution. And that’s just the beginning, as we’re continuing our groundbreaking research and development of new products such as gel capsules, bi-layered tablets, and other exciting new formulations.
All of which makes Canntab one of the best investments in this highly exciting market.
Decades of business experience spanning pharma, capital markets, legal, manufacturing, research and development.
Previously the President and CEO of Orbus Pharma, a generic drug development and manufacturing company. Prior to that Indukern Chemie AG, a Swiss pharma company. More than 20 years of experience in drug formulation and business development. Independent director of 2 public TSX companies.
Founder of First Republic Capital, Co-Founder at Fraser Mackenzie, previously Executive Vice-President and Head of Investment Banking at Standard Securities. Over 26 years of experience in investment banking and institutional sales and trading. MBA in Finance from McMaster University.
Director of Operations with over 25 years experience in the Manufacturing of, Pharmaceutical API's and finished doses, Nutraceuticals and Cosmetics. Specializes in optimizing processes to scale up production.
More than 15 years of Procurement Management in the Pharmaceutical industry. Previously was Procurement Manager and Compliance officer for Orbus Pharma inc. More than 15 years of Pharmaceutical plant GMP construction experience.
Has been a Partner at Garfinkle Biderman, specializing in corporate and commercial work, including securities. Holds a LL.N cum laude and a Quebec Civil Law degree, both from the University of Ottawa.
More than 20 years of experience in biotechnology, pharma and supplement industries. Has extensive cross-border transactional experience including IP aspects of corporate transactions.
Sheldon Inwentash is Chairman and CEO of ThreeD Capital Inc., a Toronto-based VC firm specializing in junior resources, technology and biotechnology. He co-founded Visible Genetics, the first commercial pharmacogenomics company, which was acquired by Bayer. Sheldon obtained his B.Comm from the University of Toronto and is a CA/CPA. In 2012, Sheldon received an honorary doctor of laws (LL.D) from the University of Toronto for his leadership as an entrepreneur, his philanthropy, and commitment to making a difference in the lives of children, youth and their families.
Vitor is VP and Treasurer of Romspen Investment Corporation, Canada’s largest non-bank commercial real estate lender. He has held senior finance and operational positions in the real estate, private equity and service-oriented industries. Vitor holds an MBA from the, Rotman School of Business, a CPA-CGA designation and is a member of the Institute of Corporate Directors.
Sabrina is the Vice President of the Clinical Research Association of Canada and the President of The Canadian Institute for Medical Advancement, She has 20 years of experience conducting clinical trials, including 7 studies on Cannabinoids and as such is renowned as a leader in the field.
Hamish is one of a select few who has real experience in building a successful cannabis company, as the founding COO for Bedrocan Canada, delivering over $400-million in returns for shareholders. He was responsible for the first legal international transfer of live cannabis plant material from Holland to Canada, and was accountable for the "greenfield" construction and commissioning of Bedrocan's state-of-the-art automated facility, which was acquired by Tweed (now Canopy Growth) to become the leading cannabis company in Canada. Hamish is a Professional Engineer in Ontario, earned his MBA from Schulich, and is the active Chair of the Little Geeks Foundation. He loves basketball, sailing and helping youth achieve their potential.
Dr. Eric Hatashita attended the University of Toronto Medical School and rose to be Chief Resident at Mt Sinai Hospital. Invited by the Kingdom of Saudi Arabia to assist in developing their Residency Training program, he lived and taught medicine overseas starting in 1996. During this time, he was chosen to become Family Physician to the Saudi Royal Family of King Abdullah 2000-2005 in recognition of his clinical excellence. Returning to Toronto with his family in 2005, he brings over 30 years of diverse medical experience to a private concierge medical practice, Regal Health Services Inc holding the highest honours in Family Medicine, the "FCFP."